Abstract
Learning from past failures, could firms developing antisense drugs stage a comeback?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Stabilization of human interferon-α1 mRNA by its antisense RNA
Cellular and Molecular Life Sciences Open Access 08 December 2012
-
Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection
Gene Therapy Open Access 23 December 2010
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bedikian, A.Y. et al. J. Clin. Oncol. 24, 4738–4745 (2006).
Chi, K.N. et al. J. Natl. Cancer Inst. 97, 1287–1296 (2005).
Levine, B.L. et al. Proc. Natl. Acad. Sci. USA 103, 17372–17377 (2006).
Warfield, K.L. et al. PloS Pathog. 2, e1 (2006).
Fortin, M. et al. Oligonucleotides. 16, 203–212 (2006).
Grim, D. et al. Nature 441, 537–541 (2006).
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
Negotiating the RNAi patent thicket
Lessons learnt from Genasense's failure
Web links
Rights and permissions
About this article
Cite this article
Potera, C. Antisense—down, but not out. Nat Biotechnol 25, 497–499 (2007). https://doi.org/10.1038/nbt0507-497
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0507-497
This article is cited by
-
A ribonucleoprotein octamer for targeted siRNA delivery
Nature Biomedical Engineering (2018)
-
Spinal muscular atrophy approval boosts antisense drugs
Nature Biotechnology (2017)
-
In vitro and in vivo protection against enterovirus 71 by an antisense phosphorothioate oligonucleotide
Archives of Virology (2014)
-
Stabilization of human interferon-α1 mRNA by its antisense RNA
Cellular and Molecular Life Sciences (2013)
-
Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection
Gene Therapy (2011)